These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8570124)

  • 1. Expression of pS2 estrogen-inducible protein in primary breast cancer.
    Horiguchi J; Iino Y; Takei H
    Oncology; 1996; 53(1):12-5. PubMed ID: 8570124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of pS2-protein in breast cancer].
    Kawabata K; Watanabe K; Ozaki S
    Rinsho Byori; 1996 Jul; 44(7):647-52. PubMed ID: 8741495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity.
    Correale M; Paradiso A; Abbate I; Mangia A; Dragone CD; Tedone T; Filotico R; Schittulli F; De Lena M
    Tumour Biol; 1993; 14(1):30-7. PubMed ID: 8493448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of pS2 protein in breast cancer and its relationship with estrogen and progesterone receptors].
    Díez Gibert O; Machuca I; Sebastián MA; Rosel P; Navarro MA
    Med Clin (Barc); 1996 Jun; 107(3):90-2. PubMed ID: 8754494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
    Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
    Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
    Foekens JA; Portengen H; Look MP; van Putten WL; Thirion B; Bontenbal M; Klijn JG
    Br J Cancer; 1994 Dec; 70(6):1217-23. PubMed ID: 7981080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
    Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
    Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
    Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
    Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of pS2 protein and estrogen and progesterone receptor status in breast cancer.
    Ioakim-Liossi A; Karakitsos P; Markopoulos C; Aroni K; Delivelioti K; Gogas J; Kyrkou K
    Acta Cytol; 1997; 41(3):713-6. PubMed ID: 9167689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pS2 is an independent prognostic factor for post-relapse survival in primary breast cancer.
    Jansen RL; Hupperets PS; Arends JW; Joosten-Achjanie SR; Volovics A; Hillen HF; Schouten HC
    Anticancer Res; 1998; 18(1B):577-82. PubMed ID: 9568180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of pS2 mRNA in breast cancer.
    Wysocki SJ; Iacopetta BJ; Ingram DM
    Eur J Cancer; 1994; 30A(12):1882-4. PubMed ID: 7880621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers.
    Gillesby BE; Zacharewski TR
    Breast Cancer Res Treat; 1999 Aug; 56(3):253-65. PubMed ID: 10573116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
    Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
    J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer.
    Cappelletti V; Coradini D; Scanziani E; Benini E; Silvestrini R; Di Fronzo G
    Eur J Cancer; 1992; 28A(8-9):1315-8. PubMed ID: 1515241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of ER, PR, MIB-1, pS2, and nuclear grade in FNA specimens of cT1 breast carcinomas: clinicopathological correlation.
    Angelidou E; Politi E; Sotiropoulou G; Poulianou E; Koutselini H
    Diagn Cytopathol; 2006 Aug; 34(8):547-52. PubMed ID: 16850494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].
    Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E
    Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pS2 in breast carcinoma: association with steroid hormone receptor status.
    Nikolić-Vukosavljević D; Grujić-Adanja G; Janković R; Branković-Magić M; Polić D; Jovanović D; Mitrović L
    Tumori; 1998; 84(6):691-4. PubMed ID: 10080679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.
    Ioachim E; Tsanou E; Briasoulis E; Batsis Ch; Karavasilis V; Charchanti A; Pavlidis N; Agnantis NJ
    Breast; 2003 Apr; 12(2):111-9. PubMed ID: 14659340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.